Burning Rock Biotech (NASDAQ:BNR) Stock Price Up 1% – What’s Next?

Shares of Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) rose 1% during trading on Wednesday . The company traded as high as $16.70 and last traded at $16.8650. Approximately 2,207 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 20,119 shares. The stock had previously closed at $16.70.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Burning Rock Biotech currently has an average rating of “Sell”.

Burning Rock Biotech Trading Up 1.0%

The business has a 50 day moving average of $18.22 and a 200-day moving average of $21.46. The firm has a market capitalization of $177.42 million, a P/E ratio of -21.35 and a beta of 1.49.

Burning Rock Biotech (NASDAQ:BNR) last posted its earnings results on Saturday, February 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. Burning Rock Biotech had a negative return on equity of 9.98% and a negative net margin of 10.27%.The business had revenue of $18.05 million for the quarter.

Insider Transactions at Burning Rock Biotech

In other news, Director Yusheng Han purchased 314,870 shares of Burning Rock Biotech stock in a transaction on Tuesday, March 31st. The stock was purchased at an average price of $17.36 per share, with a total value of $5,466,143.20. Following the transaction, the director directly owned 17,672,676 shares in the company, valued at $306,797,655.36. The trade was a 1.81% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 30.30% of the company’s stock.

Institutional Investors Weigh In On Burning Rock Biotech

Large investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. acquired a new stake in Burning Rock Biotech during the 3rd quarter valued at $26,000. Marshall Wace LLP acquired a new stake in Burning Rock Biotech during the 4th quarter valued at $220,000. Prospera Financial Services Inc acquired a new stake in Burning Rock Biotech during the 3rd quarter valued at $214,000. Renaissance Technologies LLC lifted its holdings in Burning Rock Biotech by 13.8% during the 1st quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after purchasing an additional 4,290 shares during the last quarter. Finally, Crcm LP lifted its holdings in Burning Rock Biotech by 13.8% during the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock valued at $1,917,000 after purchasing an additional 26,809 shares during the last quarter. Institutional investors and hedge funds own 30.03% of the company’s stock.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.